EU project aims to establish optimal therapy for blood cancer
Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL) are among the most common forms of blood cancer in adults. Depending on the stage of the disease, patients receive chemotherapy, immunotherapy or a stem cell transplant. The so-called measurable residual disease (MRD) can be used to determine whether the leukaemia is responding very well to the therapy early on in the course of treatment. Although MRD has a high predictive value for further treatment, it has not yet been sufficiently scientifically tested to serve as a binding guideline for an individual treatment recommendation. The RESOLVE research network, led by Professor Dr. Michael Heures, Senior Consultant at the Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation at Hannover Medical School (MHH), is now seeking to clarify this.